Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Neuroendocrine carcinomas (NECs) are a rare subgroup of neuroendocrine neoplasms that occasionally originate from gastro-entero-pancreatic (GEP) tract. Owing to their low incidence, evidences of the effectiveness of chemotherapy are scarce. Analogously to small cell lung cancer, platinum plus etoposide (Vp16) regimens are currently the standard treatment in first-line, while little data are available on the role of second-line treatment.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Bardasi C, Caputo F, Santini C, Cerma K, Casadei Gardini A,
Keywords: neuroendocrine carcinoma, irinotecan, survival, second line treatment, NEC, chemotherapy,
Introduction: The prognosis for pts with PD-EP-NEC is poor.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: McNamara M
Authors: McNamara M, Swain J, Craig Z, Wadsley J, Wall L,
Keywords: poorly differentiated, neuroendocrine carcinoma, second line treatment, docetaxel, liposomal irinotecan, 5-fluorouracil,
Introduction: First-line chemotherapy in metastatic neuroendocrine carcinomas (NEC) is based on etoposide and platinum. However, there is no standard for second line treatment.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Walter T
Authors: Couronne T, Fine C, Hadoux J, Lecomte T, Lorcet M,
Keywords: neuroendocrine, poorly differentiated neuroendocrine tumour, neuroendocrine carcinoma, chemotherapy, temozolomide, dacarbazine,
#1405 Capecitabine-Temozolomide in G3 Neuroendocrine Neoplasms
Introduction: There is no standard second line treatment for G3 neuroendocrine neoplasms (NENs). The sensitivity to platinum combinations of G3 NENs with a Ki67 < 50% remains unclear.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author:
Authors: Crespo G, Lopez C, Jimenez-Fonseca P, Matos I, Capdevila J,
Keywords: capecitabine, temozolomide, G3 NEN, Ki-67,
Introduction: PROMID and CLARINET trials demonstrate an improvement in PFS of SSA v. placebo in WDNET.
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author:
Authors: Marconcini R, Galli L, Antonuzzo A, Bracco E, Farnesi A,
Keywords: octreotide, lanreotide,